Navigation Links
PCMA: Skyrocketing Biotech Prices Challenge Employers, Consumers
Date:4/14/2008

WASHINGTON, April 14 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) issued the following statement in response to today's article in The New York Times on skyrocketing biotech prices:

"Americans currently spend $50 billion on biotech products and will spend $100 billion within a few years. The reason biotech drugs have such high prices is because they don't face generic competition once their patents expire. The absence of generic biotech products is a huge challenge for payors since the branded products can cost hundreds of thousands of dollars annually."

"Monopoly pricing of biotech products is wrong. Fortunately, there is a public policy solution: legislation that would establish a clear FDA pathway for approval of generic biotech products or biogenerics."

PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.


'/>"/>
SOURCE Pharmaceutical Care Management Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. PCMA: CMS Releases Proposed E-Prescribing Standards in Medicare
2. PCMA: New Study on Independent Pharmacy Reimbursements Will Raise Eyebrows on Capitol Hill
3. PCMA: New CBO Analysis Confirms Independent Pharmacy Collective Bargaining Legislation Increases Costs for Consumers and Payors
4. PCMA: 2008 Health Debate Highlights Workable Solutions Like E-Prescribing
5. PCMA: Independent Drugstore Lobbys Prompt Pay Agenda Could Cost Medicare $3.3 Billion Over the Next Decade
6. PCMA: Protect Your Pharmacy Week Should Focus on Safeguarding Part D Anti-Fraud Tools
7. Infertility Doctors: Genetic Disease Detection is Skyrocketing, Could Reshape Medicine
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Biotech Finishes on a High in August, Burrill Report Says
10. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
11. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: